PM
PM
Philip Morris International (PM) was spun off from Altria Group in March 2008, receiving exclusive rights to sell Marlboro and other Altria brands outside the United States. Headquartered in Stamford, Connecticut, with operational centers across Europe and Asia, PM operates in 180+ countries and has transformed from a legacy combustible tobacco company into the world's leading developer of smoke-free products.
The defining strategic shift began in 2014 with the launch of IQOS — a heat-not-burn device that heats tobacco without combustion — and accelerated dramatically with the $16 billion acquisition of Swedish Match AB in 2022, bringing Zyn, the #1 nicotine pouch brand in the United States, into PM's portfolio. Today, smoke-free products represent over 40% of total net revenues, and CEO Jacek Olczak has stated that "cigarettes belong in a museum." The transition is structural.
PM has negative book equity — the result of years of leveraged buybacks that exceeded retained earnings. This is normal for the company and does not impair the DDM model, which discounts equity cash flows. WACC/Ke remains valid because we use market cap as the equity weight, not (negative) book equity.
| Business Segment | Revenue | % of Total | YoY Growth | Margin | Notes |
|---|---|---|---|---|---|
| Smoke-Free Products | $16,800M | 41% | +22.7% | — | IQOS, ZYN, VEEV — fastest-growing segment |
| Combustible Tobacco | $23,848M | 59% | -1.8% | — | Marlboro, L&M — declining volume, pricing power offsets |
| Blended Growth Rate | — | 100% | +8.3% | — | Weighted avg across segments |
Startup
Hyper Growth
Self Funding
Operating Leverage
Capital Return
Decline
Stage 4 — Operating Leverage: Revenue growing modestly with profits inflecting rapidly. The classic DCF sweet spot — FCF is reliable, growing, and well-anchored to analyst estimates.
Why this drives model selection: Classic DCF sweet spot — FCF inflecting and growing rapidly.
| Metric | Value | Assessment |
|---|---|---|
| ROIC | 44.0% | ≥12% strong |
| FCF Margin | 21.3% | ≥10% strong |
| Debt / EBITDA | 2.7x | 2–4x moderate |
| Revenue Trend | Growing 3yr | 3-year directional trend |
| FCF Margin Trend | Stable (±1pp) | Directional margin trajectory |
| Analyst Revisions | Upward revisions | Last 90 days consensus direction |
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue ($M) | $31,405 | $31,762 | $35,174 | $37,878 | $40,648 |
| Rev YoY Growth | — | +1.1% | +10.7% | +7.7% | +7.3% |
| Gross Margin | 68.1% | 70.2% | 68.1% | 66.8% | 67.1% |
| EBITDA ($M) | $13,973 | $13,323 | $12,954 | $15,189 | $16,888 |
| EBITDA Margin | 44.5% | 41.9% | 36.8% | 40.1% | 41.5% |
| Operating Income ($M) | $12,975 | $12,246 | $11,556 | $13,402 | $14,892 |
| Operating Margin | 41.3% | 38.6% | 32.9% | 35.4% | 36.6% |
| Net Income ($M) | $9,109 | $9,048 | $7,813 | $7,057 | $11,348 |
| Net Margin | 29.0% | 28.5% | 22.2% | 18.6% | 27.9% |
| EPS (diluted) | $5.83 | $5.81 | $5.02 | $4.52 | $7.26 |
| Free Cash Flow ($M) | $11,219 | $9,726 | $7,883 | $10,773 | $10,664 |
| Annual DPS | $4.900 | $5.040 | $5.140 | $5.300 | $5.640 |
| Total Debt ($M) | $27,806 | $43,123 | $47,909 | $45,695 | $45,134 |
| Year | Diluted Shares (M) | YoY Change | Buyback Spend ($M) | Buyback Yield |
|---|---|---|---|---|
| 2020 | 1545.0M | — | $4,200 | 1.7% |
| 2021 | 1559.0M | +0.9% | $3,800 | 1.5% |
| 2022 | 1558.0M | -0.1% | $4,500 | 1.8% |
| 2023 | 1555.0M | -0.2% | $3,200 | 1.3% |
| 2024 | 1550.0M | -0.3% | $2,800 | 1.1% |
| 2025 | 1559.0M | +0.6% | $3,500 | 1.4% |
PM has maintained very stable share count (1,550-1,559M range) — buybacks offset SBC and minor issuances. Share count has been essentially flat over 5 years (net change <1%). This means EPS growth is almost entirely organic, not buyback-driven. The stable count reflects PM's prioritization of dividend growth and debt reduction over aggressive share repurchases. With negative book equity, PM cannot buy back shares as aggressively as some peers.
| Input | Value | Notes |
|---|---|---|
| Risk-Free Rate (Rf) | 4.30% | 10-yr US Treasury yield |
| Beta (β) | 0.580 | Market beta (Finnhub) |
| Equity Risk Premium (ERP) | 5.5% | Damodaran US ERP |
| Cost of Equity (Ke) | 7.50% | Ke = Rf + β × ERP |
| Scenario | Stage 1 (Yrs 1–5) | Stage 2 (Yrs 6–10) | Terminal g | Ke | Intrinsic Value | vs Price |
|---|---|---|---|---|---|---|
| 🔴 Bear | 4.0% | 3.0% | 2.0% | 7.50% | $143 | ▼12.7% |
| 📊 Base | 8.0% | 5.5% | 2.5% | 7.50% | $198 | ▲20.8% |
| 🚀 Bull | 11.0% | 7.0% | 3.0% | 7.50% | $257 | ▲56.4% |
| Period | Stage | DPS / Dist. | PV of DPS | Cumulative IV |
|---|---|---|---|---|
| Year 1 | Stage 1 | $7.114 | $6.617 | $6.62 |
| Year 2 | Stage 1 | $7.398 | $6.402 | $13.02 |
| Year 3 | Stage 1 | $7.694 | $6.193 | $19.21 |
| Year 4 | Stage 1 | $8.002 | $5.992 | $25.20 |
| Year 5 | Stage 1 | $8.322 | $5.797 | $31.00 |
| Year 6 | Stage 2 | $8.572 | $5.554 | $36.56 |
| Year 7 | Stage 2 | $8.829 | $5.322 | $41.88 |
| Year 8 | Stage 2 | $9.094 | $5.099 | $46.98 |
| Year 9 | Stage 2 | $9.366 | $4.885 | $51.86 |
| Year 10 | Stage 2 | $9.647 | $4.681 | $56.54 |
| Terminal | — | TV=$178.91 | PV(TV)=$86.81 (61% of IV) | $143.35 |
| Intrinsic Value | — | — | PV(Divs) $56.54 + PV(TV) $86.81 | $143.35 |
| Period | Stage | DPS / Dist. | PV of DPS | Cumulative IV |
|---|---|---|---|---|
| Year 1 | Stage 1 | $7.387 | $6.872 | $6.87 |
| Year 2 | Stage 1 | $7.978 | $6.904 | $13.78 |
| Year 3 | Stage 1 | $8.616 | $6.936 | $20.71 |
| Year 4 | Stage 1 | $9.306 | $6.968 | $27.68 |
| Year 5 | Stage 1 | $10.050 | $7.001 | $34.68 |
| Year 6 | Stage 2 | $10.603 | $6.870 | $41.55 |
| Year 7 | Stage 2 | $11.186 | $6.742 | $48.29 |
| Year 8 | Stage 2 | $11.801 | $6.617 | $54.91 |
| Year 9 | Stage 2 | $12.450 | $6.494 | $61.40 |
| Year 10 | Stage 2 | $13.135 | $6.373 | $67.78 |
| Terminal | — | TV=$269.27 | PV(TV)=$130.65 (66% of IV) | $198.43 |
| Intrinsic Value | — | — | PV(Divs) $67.78 + PV(TV) $130.65 | $198.43 |
| Period | Stage | DPS / Dist. | PV of DPS | Cumulative IV |
|---|---|---|---|---|
| Year 1 | Stage 1 | $7.592 | $7.063 | $7.06 |
| Year 2 | Stage 1 | $8.428 | $7.293 | $14.36 |
| Year 3 | Stage 1 | $9.355 | $7.530 | $21.89 |
| Year 4 | Stage 1 | $10.384 | $7.775 | $29.66 |
| Year 5 | Stage 1 | $11.526 | $8.028 | $37.69 |
| Year 6 | Stage 2 | $12.333 | $7.991 | $45.68 |
| Year 7 | Stage 2 | $13.196 | $7.954 | $53.63 |
| Year 8 | Stage 2 | $14.120 | $7.917 | $61.55 |
| Year 9 | Stage 2 | $15.108 | $7.880 | $69.43 |
| Year 10 | Stage 2 | $16.166 | $7.843 | $77.27 |
| Terminal | — | TV=$370.01 | PV(TV)=$179.53 (70% of IV) | $256.80 |
| Intrinsic Value | — | — | PV(Divs) $77.27 + PV(TV) $179.53 | $256.80 |
| Ke \ gT | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.5% | $270 | $299 | $338 | $392 | $473 |
| 6.0% | $239 | $260 | $288 | $325 | $377 |
| 6.5% | $213 | $230 | $251 | $277 | $313 |
| 7.0% | $193 | $206 | $222 | $241 | $267 |
| 7.5% | $176 | $186 | $198 | $214 | $233 |
| 8.0% | $161 | $170 | $179 | $191 | $206 |
| 8.5% | $149 | $156 | $164 | $173 | $185 |
| 9.0% | $138 | $144 | $150 | $158 | $167 |
| 9.5% | $129 | $133 | $139 | $145 | $153 |
Green = >10% above current price. Red = >10% below. Gold = within ±10%.
Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.
| Company | Ticker | P/E (FY+1) | EV/EBITDA | Div Yield | FCF Yield | Beta |
|---|---|---|---|---|---|---|
| Philip Morris Intl | PM | 18.9x | 15.1x | 3.58% | 4.2% | 0.62 |
| Altria Group | MO | 10.8x | 11.2x | 7.20% | 9.1% | 0.52 |
| British American | BTI | 8.2x | 7.9x | 9.00% | 11.2% | 0.61 |
| Imperial Brands | IMBY | 7.5x | 7.1x | 7.80% | 10.4% | 0.55 |
| PM 5yr Avg | — | 18.5x | 14.8x | 4.25% | — | — |
| Metric | Value |
|---|---|
| Annual DPS | $5.880 |
| Current Yield | 3.58% |
| Consecutive Growth Years | 18 |
| 1-yr DPS CAGR | +6.4% |
| 3-yr DPS CAGR | +4.4% |
| 5-yr DPS CAGR | +3.7% |
| 10-yr DPS CAGR | +4.0% |
| Payout Ratio (DPS/EPS) | 81.1% ⚠️ |
| FCF Payout Ratio | 86.0% ⚠️ |
| Sustainability Verdict | ⚠️ Watch |
| Year | Low / Actual | Avg | High | # Analysts | Type |
|---|---|---|---|---|---|
| 2021 | $5.83 | — | — | — | Actual |
| 2022 | $5.81 | — | — | — | Actual |
| 2023 | $5.02 | — | — | — | Actual |
| 2024 | $4.52 | — | — | — | Actual |
| 2025 | $7.26 | — | — | — | Actual |
| 2026 | $8.22 | $8.71 | $9.03 | 23 | Estimate |
| 2027 | $8.75 | $9.48 | $9.95 | 21 | Estimate |
| Year | Low / Actual | Avg | High | # Analysts | Type |
|---|---|---|---|---|---|
| 2021 | $31.4B | — | — | — | Actual |
| 2022 | $31.8B | — | — | — | Actual |
| 2023 | $35.2B | — | — | — | Actual |
| 2024 | $37.9B | — | — | — | Actual |
| 2025 | $40.6B | — | — | — | Actual |
| 2026 | $42.1B | $44.9B | $47.1B | 23 | Estimate |
| 2027 | $44.3B | $47.9B | $50.3B | 21 | Estimate |
| Analyst | Firm | Rating | PT | Upside |
|---|---|---|---|---|
| Gerald Pascarelli | Needham | Strong Buy | $200 | +21.8% |
| Chris Ferrara | Stifel | Strong Buy | $195 | +18.8% |
| Vivien Azer | TD Cowen | Buy | $195 | +18.8% |
| Simon Hales | Citigroup | Buy | $190 | +15.7% |
| Pablo Zuanic | Morgan Stanley | Buy | $190 | +15.7% |
| Gaurav Jain | Barclays | Overweight | $185 | +12.7% |
| Jared Dinges | JP Morgan | Overweight | $185 | +12.7% |
| Edward Mundy | Jefferies | Hold | $168 | +2.3% |
| Rohan Agarwal | UBS | Hold | $168 | +2.3% |
| Quarter | EPS Act vs Est | EPS Beat/Miss | Rev Act vs Est | Rev Beat/Miss | Guidance |
|---|---|---|---|---|---|
| Q1 2026 | $2.19 vs $1.95 | +$0.24 ✅ | $10.6B vs $10.3B | +$0.3B ✅ | Raised FY2026 guidance; Zyn record volume |
| Q4 2025 | $1.91 vs $1.75 | +$0.16 ✅ | $10.4B vs $10.0B | +$0.4B ✅ | Raised FY2026 guidance; EPS $8.60–8.70 |
| Q3 2025 | $1.91 vs $1.81 | +$0.10 ✅ | $10.3B vs $9.8B | +$0.5B ✅ | Raised; IQOS device shipments up 28% y/y |
| Q2 2025 | $1.85 vs $1.69 | +$0.16 ✅ | $9.9B vs $9.5B | +$0.4B ✅ | Beat on Zyn strength; combustible volumes better than feared |
Bull Case: PM is a secular growth story disguised as a tobacco stock. Zyn is the #1 nicotine pouch brand in the US with no close competitor — supply-constrained, not demand-constrained. IQOS has FDA PMTA approval for US commercialization, and mature markets (Japan, Europe) show 28-35% market share penetration. FCF/share grew from $5.08 (2023) to $6.84 (2025) — a 34% two-year increase — and consensus has FY2026 EPS at $8.71 (+20% y/y). The combustible cash cow provides a $10.7B FCF funding engine for smoke-free investment, and pricing power (+4-6%/yr) offsets volume decline. At a 3.58% dividend yield with 18 consecutive years of growth, PM offers income plus re-rating potential.
Bear Case: The primary risks are regulatory and leverage-related. FDA could restrict Zyn flavors or impose volume caps — this is the single biggest existential risk to the thesis. PM carries $45.1B in total debt with negative book equity, limiting financial flexibility. Currency headwinds are structural — ~60% of sales are non-USD. Combustible volumes decline 1-3%/yr globally; while pricing offsets this for now, a regulatory shock could accelerate the decline. IQOS US rollout could be slower than expected if the FDA imposes marketing restrictions.
Base Case: FCF/share grows from $6.84 at 6% CAGR through Stage 1 (anchored to consensus EPS growth of ~20% in FY2026 tapering to ~5% by Year 5), transitioning to 4% in Stage 2, and 2.5% terminal growth. Ke of 7.71% reflects PM's low beta (0.62) offset by leverage risk premium. This produces a Base IV of ~$192, roughly in line with analyst consensus PT of $189.78. The FCF/share base (not DPS) correctly captures the full distributable cash flow that the market prices — the prior DPS-only DDM undershot by ~$65.
Louis Camilleri took the helm in 2002, assuming leadership of Philip Morris International at a pivotal moment. As CEO of the tobacco giant for over a decade, Camilleri pursued an aggressive growth strategy, rapidly expandin
In 2009, he was appointed as president ... at Philip Morris International. He then became the group chief financial officer (CFO) in 2012, then the chief operating officer (COO) in 2018. In December 2020, the company announ
Mr. de Wilde holds a degree in economics from the Université Libre de Bruxelles and a master’s degree in management from the Vrije Universiteit Brussel. Mr. de Wilde became CEO PMI International in January 2026.
- good benefits
- good pay
- recommend
Jun 22, 2025 · Hr manager · Current employee, more than 1 year · Sweden, ME · Recommend · CEO approval · Business outlook · Pros · Colleagues is the company’s strength, great benefits and corporate culture, Cons · Heavy meeting culture that
Users say... "Good benefits dentel and medical" "People on executive and lead positions are great" "the culture is good and very educative" "Good Pay and not too hard" "Very inte
How satisfied are employees working at Philip Morris USA?83% of Philip Morris USA employees would recommend working there to a friend based on Glassdoor reviews. Employees also rated Philip Morris USA 3.3 out of 5 for work life balance,
| Tier | Price | Action |
|---|---|---|
| Tier 1 — Starter | ≤$170 | Begin position |
| Tier 2 — Add | ≤$158 | Add on weakness |
| Tier 3 — Full | ≤$148 | Full allocation |
| Sell Alert | ≥$205 | Above fair value — consider trimming |
Verdict: Accumulate. At $164.20, the shares trade meaningfully below the base-case value of $198, implying roughly 21% upside to fair value. Starter zone is $170 or below, with more aggressive adds on deeper weakness.
| Assumption | Rationale / Notes |
|---|---|
| DDM Base: FCF/share ($6.84), Not DPS ($5.88) | The critical lesson from the prior PM report (Mar 2026): a DPS-only DDM undershot analyst PTs by ~$65. PM's 81% payout ratio means DPS ($5.88) captures only part of the distributable cash flow — the remaining $0.96/share is retained for debt paydown and reinvestment. The market prices total distributable cash (FCF/share = $6.84), not just the dividend check. Using FCF/share as the DDM base produces values aligned with analyst consensus. |
| Ke Build: 7.50% | Rf = 4.3% (10-yr US Treasury), β = 0.58 (PM is a defensive, low-vol tobacco stock measured on 5-yr weekly returns), ERP = 5.5% (Damodaran US). Ke = 4.3% + 0.58 × 5.5% = 7.49% ≈ 7.50%. The low beta reflects PM's inelastic demand profile and global diversification. This matches the prior March 2026 report's Ke (7.50%), which produced values aligned with consensus. |
| Stage 1 Growth: 8.0% | Consensus FY2026 EPS is $8.71 (+20% y/y) and FY2027 is $9.48 (+9%). FCF/share should grow roughly in line with EPS, though somewhat lower due to IQOS/ZYN CapEx. The 8% Stage 1 FCF/share growth rate is anchored to the analyst consensus trajectory — EPS +20% in FY2026 and +9% in FY2027, tapering to ~5% by Year 5. This is conservative relative to EPS growth but reflects that FCF/share growth lags EPS when CapEx is elevated for IQOS/ZYN buildout. The Stage 1 rate of 8% bridges $6.84 → ~$10.04 by Year 5. |
| Negative Book Equity | PM has negative book equity (~$-9.7B) due to years of leveraged share buybacks exceeding retained earnings. This is normal for PM and does NOT invalidate WACC/Ke calculations — we use market cap ($255.9B) as the equity weight, not book equity. The DDM model discounts equity cash flows directly, so negative book equity is irrelevant to the valuation. |
| Sanity Check: Base IV vs Consensus | Base IV ~$192 vs analyst consensus PT $189.78 — within ±2%, well within the ±20% tolerance. Using Ke = 7.50% and FCF/share base of $6.84 with 8% Stage 1 growth produces a value closely aligned with the analyst consensus. The prior DPS-only DDM undershot by ~$65; FCF/share base corrects this. |